X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) Short Interest Down 33.4% in February

X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) saw a large decrease in short interest in February. As of February 15th, there was short interest totalling 11,060,000 shares, a decrease of 33.4% from the January 31st total of 16,610,000 shares. Based on an average daily trading volume, of 4,110,000 shares, the short-interest ratio is presently 2.7 days.

Insider Activity at X4 Pharmaceuticals

In other news, CEO Paula Ragan sold 76,473 shares of the stock in a transaction dated Friday, January 24th. The stock was sold at an average price of $0.45, for a total value of $34,412.85. Following the transaction, the chief executive officer now directly owns 1,087,386 shares of the company’s stock, valued at approximately $489,323.70. This represents a 6.57 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CFO Adam S. Mostafa sold 74,773 shares of the stock in a transaction dated Friday, January 24th. The shares were sold at an average price of $0.45, for a total value of $33,647.85. The disclosure for this sale can be found here. Insiders have sold 202,663 shares of company stock valued at $91,198 in the last ninety days. Corporate insiders own 1.62% of the company’s stock.

Institutional Investors Weigh In On X4 Pharmaceuticals

Hedge funds and other institutional investors have recently made changes to their positions in the company. Acorn Capital Advisors LLC acquired a new position in shares of X4 Pharmaceuticals in the 4th quarter valued at $5,363,000. GSA Capital Partners LLP acquired a new position in shares of X4 Pharmaceuticals in the third quarter worth about $340,000. JPMorgan Chase & Co. raised its position in shares of X4 Pharmaceuticals by 501.0% in the fourth quarter. JPMorgan Chase & Co. now owns 459,653 shares of the company’s stock worth $337,000 after acquiring an additional 383,177 shares during the period. Jane Street Group LLC grew its position in shares of X4 Pharmaceuticals by 134.9% during the 4th quarter. Jane Street Group LLC now owns 583,483 shares of the company’s stock valued at $428,000 after acquiring an additional 335,036 shares during the period. Finally, Deutsche Bank AG grew its position in shares of X4 Pharmaceuticals by 559.6% during the 4th quarter. Deutsche Bank AG now owns 267,628 shares of the company’s stock valued at $195,000 after acquiring an additional 227,051 shares during the period. Institutional investors and hedge funds own 72.03% of the company’s stock.

Analysts Set New Price Targets

Several equities analysts recently weighed in on XFOR shares. Stifel Nicolaus cut their price target on shares of X4 Pharmaceuticals from $5.00 to $4.00 and set a “buy” rating on the stock in a report on Thursday, November 14th. HC Wainwright reiterated a “buy” rating and issued a $1.50 price objective on shares of X4 Pharmaceuticals in a research note on Friday, February 7th.

X4 Pharmaceuticals Stock Up 6.9 %

X4 Pharmaceuticals stock opened at $0.40 on Friday. The firm has a market cap of $67.38 million, a price-to-earnings ratio of -4.39 and a beta of 0.12. X4 Pharmaceuticals has a 52 week low of $0.26 and a 52 week high of $1.60. The business’s 50-day moving average price is $0.57 and its 200 day moving average price is $0.57. The company has a quick ratio of 4.80, a current ratio of 4.89 and a debt-to-equity ratio of 1.26.

X4 Pharmaceuticals Company Profile

X4 Pharmaceuticals, Inc, a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase III clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome; and Phase II clinical trial to treat congenital, idiopathic, or cyclic neutropenia.